{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:22:50Z","timestamp":1793161370189,"version":"4.5.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.beem.2025.101977","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:40:08Z","timestamp":1737546008000},"page":"101977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Systemic therapy for patients with metastatic pheochromocytoma and paraganglioma"],"prefix":"10.1016","volume":"39","author":[{"given":"Alessa","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydira","family":"del Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"N\u00f6lting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.beem.2025.101977_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.beem.2025.101977_bib2","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens"},{"issue":"5","key":"10.1016\/j.beem.2025.101977_bib3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.beem.2025.101977_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.beem.2025.101977_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"Nolting","year":"2022","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.beem.2025.101977_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"issue":"4","key":"10.1016\/j.beem.2025.101977_bib7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"12","key":"10.1016\/j.beem.2025.101977_bib8","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1245\/s10434-017-6074-1","article-title":"Clinical predictors of malignancy in patients with pheochromocytoma and paraganglioma","volume":"24","author":"Dhir","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.beem.2025.101977_bib9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2025.101977_bib10","article-title":"TNM staging and overall survival in patients with pheochromocytoma and sympathetic paraganglioma","author":"Jimenez","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2025.101977_bib11","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2025.101977_bib12","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1245\/s10434-020-08221-2","article-title":"Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine and Head and Neck Disease Site Working Group, Part 2 of 2: Perioperative Management and Outcomes of Pheochromocytoma and Paraganglioma","volume":"27","author":"Patel","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.beem.2025.101977_bib13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MED.0000000000000330","article-title":"Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials","volume":"24","author":"Roman-Gonzalez","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"10.1016\/j.beem.2025.101977_bib14","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA: a Cancer J Clin"},{"issue":"4","key":"10.1016\/j.beem.2025.101977_bib15","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","article-title":"Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma","volume":"98","author":"Ayala-Ramirez","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2025.101977_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114122","article-title":"Adverse skeletal related events in patients with bone-metastatic pheochromocytoma\/paraganglioma","volume":"208","author":"Lagana","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beem.2025.101977_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2024.101116","article-title":"Management of metastatic pheochromocytomas and paragangliomas: when and what","volume":"51","author":"Sukrithan","year":"2024","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.beem.2025.101977_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2024.112344","article-title":"Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice","volume":"592","author":"Varghese","year":"2024","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2025.101977_bib19","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","article-title":"Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma","volume":"15","author":"Jimenez","year":"2013","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.beem.2025.101977_bib20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s12020-017-1515-y","article-title":"Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma","volume":"59","author":"Gravel","year":"2018","journal-title":"Endocrine"},{"issue":"11","key":"10.1016\/j.beem.2025.101977_bib21","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.beem.2025.101977_bib22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"10.1016\/j.beem.2025.101977_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11071018","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine","volume":"11","author":"Jimenez","year":"2019","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.beem.2025.101977_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"issue":"10431","key":"10.1016\/j.beem.2025.101977_bib25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.beem.2025.101977_bib26","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1470-2045(24)00133-5","article-title":"Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial","volume":"25","author":"Jimenez","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.beem.2025.101977_bib27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"issue":"3","key":"10.1016\/j.beem.2025.101977_bib28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement","volume":"20","author":"Taieb","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2025.101977_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","volume":"11","author":"Taieb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2025.101977_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241301359","article-title":"Perspective review: lessons from successful clinical trials and real-world studies of systemic therapy for metastatic pheochromocytomas and paragangliomas","volume":"16","author":"Jimenez","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.beem.2025.101977_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1055\/a-2204-4549","article-title":"Animal and cell culture models of PPGLs - achievements and limitations","volume":"56","author":"Karna","year":"2024","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2025.101977_bib32","series-title":"Talking About Rare Diseases: A Compendium on Rare Diseases and Online News","first-page":"1","author":"Oliveira","year":"2020"},{"issue":"3Pt 2","key":"10.1016\/j.beem.2025.101977_bib33","first-page":"I18","article-title":"Treatment of malignant pheochromocytoma with combination chemotherapy","volume":"7","author":"Keiser","year":"1985","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.beem.2025.101977_bib34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/1097-0142(197801)41:1<56::AID-CNCR2820410110>3.0.CO;2-2","article-title":"Neuroblastoma in the adult: effective combination chemotherapy","volume":"41","author":"Dosik","year":"1978","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beem.2025.101977_bib35","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.beem.2025.101977_bib36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/mpo.2950220607","article-title":"Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"22","author":"Wu","year":"1994","journal-title":"Med Pedia Oncol"},{"issue":"3","key":"10.1016\/j.beem.2025.101977_bib37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/EJE-15-0456","article-title":"Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma","volume":"173","author":"Thosani","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2025.101977_bib38","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.beem.2025.101977_bib39","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/cncr.23812","article-title":"Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients","volume":"113","author":"Huang","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.beem.2025.101977_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma","volume":"4","author":"Tanabe","year":"2013","journal-title":"Horm Cancer"},{"issue":"1","key":"10.1016\/j.beem.2025.101977_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11912-022-01197-0","article-title":"New directions in treatment of metastatic or advanced pheochromocytomas and sympathetic paragangliomas: an American, contemporary, pragmatic approach","volume":"24","author":"Jimenez","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"10.1016\/j.beem.2025.101977_bib42","doi-asserted-by":"crossref","first-page":"L51","DOI":"10.1530\/ERC-17-0086","article-title":"SDHB mutation carriers with malignant pheochromocytoma respond better to CVD","volume":"24","author":"Fishbein","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.beem.2025.101977_bib43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12020-009-9219-6","article-title":"Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma","volume":"36","author":"He","year":"2009","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.beem.2025.101977_bib44","first-page":"1093","article-title":"Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer","volume":"3","author":"Dhodapkar","year":"1997","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.beem.2025.101977_bib45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.beem.2025.101977_bib46","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2025.101977_bib47","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"issue":"11","key":"10.1016\/j.beem.2025.101977_bib48","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.beem.2025.101977_bib49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/ERC-21-0392","article-title":"SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma","volume":"29","author":"Perez","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.beem.2025.101977_bib50","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0236","article-title":"Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma\/paraganglioma","volume":"30","author":"Jimenez","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.beem.2025.101977_bib51","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/MED.0000000000000544","article-title":"High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease","volume":"27","author":"Jimenez","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"10.1016\/j.beem.2025.101977_bib52","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients","volume":"20","author":"Loh","year":"1997","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"10.1016\/j.beem.2025.101977_bib53","first-page":"269","article-title":"Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience","volume":"35","author":"Shapiro","year":"1991","journal-title":"J Nucl Biol Med"},{"issue":"3","key":"10.1016\/j.beem.2025.101977_bib54","first-page":"S187","article-title":"Diagnosis and treatment of phaeochromocytoma with 131I-metaiodobenzylguanidine","volume":"2","author":"Fischer","year":"1984","journal-title":"J Hypertens Suppl"},{"issue":"3","key":"10.1016\/j.beem.2025.101977_bib55","first-page":"299","article-title":"Comparison of high-specific-activity ultratrace 123\/131I-MIBG and carrier-added 123\/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution","volume":"25","author":"Barrett","year":"2010","journal-title":"Cancer Biother Radio"},{"key":"10.1016\/j.beem.2025.101977_bib56","first-page":"209","article-title":"Treatment of malignant pheochromocytoma with a new radiopharmaceutical","volume":"96","author":"Sisson","year":"1983","journal-title":"Trans Assoc Am Physicians"},{"issue":"25","key":"10.1016\/j.beem.2025.101977_bib57","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beem.2025.101977_bib58","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","article-title":"131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma","volume":"35","author":"Gedik","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.beem.2025.101977_bib59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/COC.0b013e31819e2c28","article-title":"Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience","volume":"33","author":"Shilkrut","year":"2010","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beem.2025.101977_bib60","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s12149-013-0755-z","article-title":"Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma","volume":"27","author":"Wakabayashi","year":"2013","journal-title":"Ann Nucl Med"},{"issue":"6","key":"10.1016\/j.beem.2025.101977_bib61","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0039-6060(03)00426-4","article-title":"Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma","volume":"134","author":"Safford","year":"2003","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.beem.2025.101977_bib62","first-page":"100","article-title":"131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy","volume":"54","author":"Castellani","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.beem.2025.101977_bib63","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1210\/clinem\/dgz074","article-title":"Long-term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131-I MIBG","volume":"105","author":"Thorpe","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2025.101977_bib64","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2017-02030","article-title":"Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma","volume":"103","author":"Noto","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.beem.2025.101977_bib65","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/RLU.0000000000005184","article-title":"High-specific-activity 131 I-MIBG for the treatment of advanced pheochromocytoma and paraganglioma","volume":"49","author":"Al-Ward","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"7","key":"10.1016\/j.beem.2025.101977_bib66","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands","volume":"28","author":"Reubi","year":"2001","journal-title":"Eur J Nucl Med"},{"issue":"11","key":"10.1016\/j.beem.2025.101977_bib67","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1210\/jc.2003-030262","article-title":"Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy","volume":"88","author":"Mundschenk","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2025.101977_bib68","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.beem.2025.101977_bib69","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2967\/jnumed.110.075226","article-title":"Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors","volume":"51","author":"Menda","year":"2010","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.beem.2025.101977_bib70","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.beem.2025.101977_bib71","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2025.101977_bib72","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas","volume":"115","author":"Nastos","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.beem.2025.101977_bib73","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.98.C22","article-title":"editors. Phase 2 trial of lu-177-DOTATATE in metastatic or inoperable pheochromocytoma\/paraganglioma: interim analysis results","author":"Lin","year":"2023","journal-title":"Endocr Abstr"},{"issue":"6","key":"10.1016\/j.beem.2025.101977_bib74","first-page":"1007","article-title":"Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides","volume":"47","author":"Boyd","year":"2006","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.beem.2025.101977_bib75","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/bc00018a006","article-title":"1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation","volume":"3","author":"Vaidyanathan","year":"1992","journal-title":"Bioconjug Chem"},{"issue":"6","key":"10.1016\/j.beem.2025.101977_bib76","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00259-017-3919-6","article-title":"Antitumor effects of radionuclide treatment using alpha-emitting meta-(211)At-astato-benzylguanidine in a PC12 pheochromocytoma model","volume":"45","author":"Ohshima","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.beem.2025.101977_bib77","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s12149-022-01765-1","article-title":"Manual on the proper use of meta-[(211)At] astato-benzylguanidine ([(211)At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)","volume":"36","author":"Ukon","year":"2022","journal-title":"Ann Nucl Med"},{"issue":"9","key":"10.1016\/j.beem.2025.101977_bib78","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted alpha-emitter therapy with (212)Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.beem.2025.101977_bib79","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2265.1995.tb01877.x","article-title":"Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial","volume":"42","author":"Plouin","year":"1995","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2025.101977_bib80","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2265.2002.01658.x","article-title":"Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma","volume":"57","author":"Lamarre-Cliche","year":"2002","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2025.101977_bib81","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/ejendo\/lvad146","article-title":"Responses to systemic therapy in metastatic pheochromocytoma\/paraganglioma: a retrospective multicenter cohort study","volume":"189","author":"Fischer","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.beem.2025.101977_bib82","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/ERC-20-0043","article-title":"Antiangiogenic therapies for pheochromocytoma and paraganglioma","volume":"27","author":"Jimenez","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.beem.2025.101977_bib83","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2008-1972","article-title":"Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma andother von Hippel-Lindau disease-related tumors","volume":"94","author":"Jimenez","year":"2009","journal-title":"Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2025.101977_bib84","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.beem.2025.101977_bib85","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O'Kane","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.beem.2025.101977_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114276","article-title":"Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: the phase 2 non-randomized SUTNET clinical trial","volume":"209","author":"Nasca","year":"2024","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.beem.2025.101977_bib87","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40265-014-0265-x","article-title":"Cabozantinib: a review of its use in patients with medullary thyroid cancer","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.beem.2025.101977_bib88","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4602","article-title":"Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma","author":"Fojo","year":"2024","journal-title":"Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.beem.2025.101977_bib89","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","article-title":"Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.beem.2025.101977_bib90","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac044","article-title":"Lenvatinib as a therapeutic option in unresectable metastatic pheochromocytoma and paragangliomas","volume":"6","author":"Hassan Nelson","year":"2022","journal-title":"J Endocr Soc"},{"issue":"2","key":"10.1016\/j.beem.2025.101977_bib91","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1634\/theoncologist.2019-0407","article-title":"Lenvatinib in management of solid tumors","volume":"25","author":"Hao","year":"2020","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.beem.2025.101977_bib92","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae061","article-title":"Anlotinib for metastatic progressed pheochromocytoma and paraganglioma: a retrospective study of real-world data","volume":"8","author":"Tian","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.beem.2025.101977_bib93","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e15000","article-title":"A phase 2 study of anlotinib in patients with metastatic pheochromocytoma\/paraganglioma","author":"Tong","year":"2022","journal-title":"Am Soc Clin Oncol"},{"issue":"10275","key":"10.1016\/j.beem.2025.101977_bib94","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beem.2025.101977_bib95","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beem.2025.101977_bib96","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.beem.2025.101977_bib97","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2025.101977_bib98","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","author":"Chan","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beem.2025.101977_bib99","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/oncolo\/oyac083","article-title":"Phase II study of cabozantinib in patients with bone metastasis","volume":"27","author":"Choy","year":"2022","journal-title":"Oncologist"},{"issue":"48","key":"10.1016\/j.beem.2025.101977_bib100","doi-asserted-by":"crossref","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","article-title":"Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma","volume":"113","author":"Spranger","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.beem.2025.101977_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082307","article-title":"Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas","volume":"12","author":"Jimenez","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.beem.2025.101977_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16122191","article-title":"Immunohistochemical profiling of SSTR2 and HIF-2alpha with the tumor microenvironment in pheochromocytoma and paraganglioma","volume":"16","author":"Uchihara","year":"2024","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.beem.2025.101977_bib103","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/endrev\/bnae005","article-title":"The immune landscape of pheochromocytoma and paraganglioma: current advances and perspectives","volume":"45","author":"Uher","year":"2024","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2025.101977_bib104","doi-asserted-by":"crossref","DOI":"10.1007\/s10528-024-10733-5","article-title":"Constructing a novel amino acid metabolism signature: a new perspective on pheochromocytoma diagnosis, immune landscape, and immunotherapy","author":"Yan","year":"2024","journal-title":"Biochem Genet"},{"issue":"3","key":"10.1016\/j.beem.2025.101977_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030467","article-title":"Endocrine and neuroendocrine tumors special issue-checkpoint inhibitors for adrenocortical carcinoma and metastatic pheochromocytoma and paraganglioma: do they work?","volume":"14","author":"Jimenez","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.beem.2025.101977_bib106","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia-inducible factor 2 alpha (HIF2alpha) inhibitors: targeting genetically driven tumor hypoxia","volume":"44","author":"Toledo","year":"2023","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.beem.2025.101977_bib107","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.beem.2025.101977_bib108","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.beem.2025.101977_bib109","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von hippel-lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.beem.2025.101977_bib110","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","article-title":"Belzutifan, a potent HIF2alpha inhibitor, in the Pacak-Zhuang syndrome","volume":"385","author":"Kamihara","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.beem.2025.101977_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184602","article-title":"Insights into mechanisms of pheochromocytomas and paragangliomas driven by known or new genetic drivers","volume":"13","author":"Flores","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.beem.2025.101977_bib112","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.89.T5","article-title":"editors. A phase 2 open-Label study of belzutifan (a HIF-2 [alpha] inhibitor) monotherapy in patients with advanced\/metastatic pheochromocytoma\/paraganglioma or pancreatic neuroendocrine tumors","author":"Jimenez","year":"2023","journal-title":"Endocr Abstr"},{"issue":"11","key":"10.1016\/j.beem.2025.101977_bib113","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1210\/en.2019-00410","article-title":"Synergistic highly potent targeted drug combinations in different pheochromocytoma models including human tumor cultures","volume":"160","author":"Fankhauser","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2025.101977_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101913","article-title":"Pre-clinical phaeochromocytoma and paraganglioma models: cell lines, animal models, and a human primary culture model","author":"Wang","year":"2024","journal-title":"Best Pr Res Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2025.101977_bib115","first-page":"2892","article-title":"Opposing effects of cannabidiol in patient-derived neuroendocrine tumor, pheochromocytoma\/paraganglioma primary cultures","volume":"109","author":"Wang","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2025.101977_bib116","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1530\/ERC-21-0355","article-title":"Personalized drug testing in human pheochromocytoma\/paraganglioma primary cultures","volume":"29","author":"Wang","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.beem.2025.101977_bib117","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3892\/ijmm.2016.2779","article-title":"Overlapping molecular pathways between cannabinoid receptors type 1 and 2 and estrogens\/androgens on the periphery and their involvement in the pathogenesis of common diseases (Review)","volume":"38","author":"Dobovisek","year":"2016","journal-title":"Int J Mol Med"},{"issue":"1","key":"10.1016\/j.beem.2025.101977_bib118","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/ejendo\/lvae163","article-title":"Impact of sex hormones on pheochromocytomas, paragangliomas, and gastroenteropancreatic neuroendocrine tumors","volume":"192","author":"Wang","year":"2025","journal-title":"Eur J Endocrinol"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X25000107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X25000107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T11:51:32Z","timestamp":1738324292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X25000107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1521690X25000107"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2025.101977","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapy for patients with metastatic pheochromocytoma and paraganglioma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2025.101977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101977"}}